Reshma Kewalramani

Reshma Kewalramani

CEO and PresidentatVertex Pharmaceuticals Inc / Ma· In proxies 2021–2025

Pay in FY2025-2% from the year before · Vertex Pharmaceuticals Inc / Ma stock +12.6% the same year

Reshma Kewalramani was paid $21.1M in FY2025 (Dec), down 2%. Vertex Pharmaceuticals Inc / Ma stock rose 12.6% that year.

Pay$100 in the stock at the end of FY20 → $192
Pay is from the Summary Compensation Table of each Vertex Pharmaceuticals Inc / Ma proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Vertex Pharmaceuticals Inc / MaPublic company · 5 yr
    • CEO and President2021 – Present · 5 yrStock in role +126%

Roles come from the proxy statements of each company.

Boards1

  • Vertex Pharmaceuticals Inc / MaDirector · 5 yr on the boardNot independent—Paid as an executive

Board seats come from each company's latest proxy statement.

Activity

No new filings about this person in the feed.

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?